Unit of Pharmacology, University Hospital of Pisa, Pisa, Italy.
Postgrad Med. 2010 Jul;122(4):49-65. doi: 10.3810/pgm.2010.07.2175.
General consensus exists about the need to avoid drug intake as much as possible during pregnancy due to the lack of thorough evidence about the safety of pharmacologic treatments during gestation for both mothers and fetuses. In this respect, the overall safety profile of selective serotonin reuptake inhibitors (SSRIs) in pregnancy remains unclear. This article reviews current evidence about the safety of each SSRI during pregnancy in order to describe their specific teratogenic potential, with a particular focus on major and cardiovascular malformations, and to verify whether such toxicity can be considered as a class effect. The literature review included controlled studies and meta-analyses (retrieved using PsychINFO, EMBASE, and Medline from January 1966 to May 2010) from which the risk of major and/or cardiovascular malformations associated with a specific SSRI (ie, fluoxetine, paroxetine, sertraline, citalopram, escitalopram, and fluvoxamine) could be estimated. Although there is evidence to support the association between birth defects and first-trimester exposure to paroxetine, findings from the studies reviewed suggest a teratogenic potential of the whole SSRI class, consistent with preclinical evidence. These teratogenic effects are mainly in the heart region, and they are often described as septal defects. It may be suggested that the higher frequency of teratogenic effects reported for paroxetine might depend on specific pharmacologic features of this drug compared with other SSRIs, although it is difficult to test this hypothesis. It is noteworthy that current evidence on SSRI teratogenicity stems from studies affected by several methodological weaknesses (ie, lack of investigations using control groups of untreated depressed mothers, confounding by indication, and recall bias). Accordingly, we are not yet able to rule out the possibility that positive associations, as determined in some studies, result from analyses of poor quality.
人们普遍认为,由于缺乏充分的证据证明妊娠期间药物治疗对母亲和胎儿的安全性,怀孕期间应尽量避免药物摄入。在这方面,选择性 5-羟色胺再摄取抑制剂(SSRIs)在妊娠期间的总体安全性仍不清楚。本文回顾了目前关于每种 SSRIs 在妊娠期间安全性的证据,以便描述其特定的致畸潜力,特别是重点关注主要和心血管畸形,并验证这种毒性是否可以被认为是一种药物类别效应。文献综述包括对照研究和荟萃分析(使用 PsychINFO、EMBASE 和 Medline 从 1966 年 1 月至 2010 年 5 月检索),从中可以估计与特定 SSRI(即氟西汀、帕罗西汀、舍曲林、西酞普兰、艾司西酞普兰和氟伏沙明)相关的主要和/或心血管畸形的风险。尽管有证据支持与头三个月接触帕罗西汀相关的出生缺陷之间存在关联,但综述研究结果表明整个 SSRIs 类别的致畸潜力,与临床前证据一致。这些致畸作用主要发生在心脏区域,通常被描述为间隔缺损。可能表明,与其他 SSRIs 相比,帕罗西汀报告的致畸作用频率更高,可能取决于该药的特定药理特征,尽管很难检验这一假设。值得注意的是,目前关于 SSRIs 致畸性的证据来自于受多种方法学弱点影响的研究(即缺乏对未经治疗的抑郁母亲对照组的调查、适应症混淆和回忆偏差)。因此,我们还不能排除一些研究中确定的阳性关联是由于分析质量较差所致的可能性。